ERBB oncogene proteins as targets for monoclonal antibodies

O. L. Polanovski, E. N. Lebedenko, S. M. Deyev

Результат исследований: Материалы для журналаОбзорная статья

34 Цитирования (Scopus)

Выдержка

General properties of the family of tyrosine kinase ERBB receptors are considered in connection with their role in the generation of cascades of signal transduction in normal and tumor cells. Causes of acquisition of oncogene features by genes encoding these receptors and their role in tumorigenesis are analyzed. Anti-ERBB monoclonal antibodies approved for therapy are described in detail, and mechanisms of their antitumor activity and development of resistance to them are reviewed. The existing and the most promising strategies for creating and using monoclonal antibodies and their derivatives for therapy of cancer are discussed.

Язык оригиналаАнглийский
Страницы (с-по)227-245
Число страниц19
ЖурналBiochemistry (Moscow)
Том77
Номер выпуска3
DOI
СостояниеОпубликовано - мар 2012
Опубликовано для внешнего пользованияДа

Отпечаток

Oncogene Proteins
Monoclonal Antibodies
Signal transduction
Gene encoding
Receptor Protein-Tyrosine Kinases
Oncogenes
Protein-Tyrosine Kinases
Tumors
Signal Transduction
Neoplasms
Carcinogenesis
Cells
Derivatives
Therapeutics
Genes

ASJC Scopus subject areas

  • Biochemistry
  • Medicine(all)

Цитировать

ERBB oncogene proteins as targets for monoclonal antibodies. / Polanovski, O. L.; Lebedenko, E. N.; Deyev, S. M.

В: Biochemistry (Moscow), Том 77, № 3, 03.2012, стр. 227-245.

Результат исследований: Материалы для журналаОбзорная статья

Polanovski, O. L. ; Lebedenko, E. N. ; Deyev, S. M. / ERBB oncogene proteins as targets for monoclonal antibodies. В: Biochemistry (Moscow). 2012 ; Том 77, № 3. стр. 227-245.
@article{fbe64afa165e43e18aa106880155c712,
title = "ERBB oncogene proteins as targets for monoclonal antibodies",
abstract = "General properties of the family of tyrosine kinase ERBB receptors are considered in connection with their role in the generation of cascades of signal transduction in normal and tumor cells. Causes of acquisition of oncogene features by genes encoding these receptors and their role in tumorigenesis are analyzed. Anti-ERBB monoclonal antibodies approved for therapy are described in detail, and mechanisms of their antitumor activity and development of resistance to them are reviewed. The existing and the most promising strategies for creating and using monoclonal antibodies and their derivatives for therapy of cancer are discussed.",
keywords = "EGFR, HER2/neu, Herceptin, Receptor tyrosine kinases ERBB1-4, Signaling cascades",
author = "Polanovski, {O. L.} and Lebedenko, {E. N.} and Deyev, {S. M.}",
year = "2012",
month = "3",
doi = "10.1134/S0006297912030029",
language = "English",
volume = "77",
pages = "227--245",
journal = "Biochemistry. Biokhimiia",
issn = "0006-2979",
publisher = "Maik Nauka-Interperiodica Publishing",
number = "3",

}

TY - JOUR

T1 - ERBB oncogene proteins as targets for monoclonal antibodies

AU - Polanovski, O. L.

AU - Lebedenko, E. N.

AU - Deyev, S. M.

PY - 2012/3

Y1 - 2012/3

N2 - General properties of the family of tyrosine kinase ERBB receptors are considered in connection with their role in the generation of cascades of signal transduction in normal and tumor cells. Causes of acquisition of oncogene features by genes encoding these receptors and their role in tumorigenesis are analyzed. Anti-ERBB monoclonal antibodies approved for therapy are described in detail, and mechanisms of their antitumor activity and development of resistance to them are reviewed. The existing and the most promising strategies for creating and using monoclonal antibodies and their derivatives for therapy of cancer are discussed.

AB - General properties of the family of tyrosine kinase ERBB receptors are considered in connection with their role in the generation of cascades of signal transduction in normal and tumor cells. Causes of acquisition of oncogene features by genes encoding these receptors and their role in tumorigenesis are analyzed. Anti-ERBB monoclonal antibodies approved for therapy are described in detail, and mechanisms of their antitumor activity and development of resistance to them are reviewed. The existing and the most promising strategies for creating and using monoclonal antibodies and their derivatives for therapy of cancer are discussed.

KW - EGFR

KW - HER2/neu

KW - Herceptin

KW - Receptor tyrosine kinases ERBB1-4

KW - Signaling cascades

UR - http://www.scopus.com/inward/record.url?scp=84862684871&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862684871&partnerID=8YFLogxK

U2 - 10.1134/S0006297912030029

DO - 10.1134/S0006297912030029

M3 - Review article

AN - SCOPUS:84862684871

VL - 77

SP - 227

EP - 245

JO - Biochemistry. Biokhimiia

JF - Biochemistry. Biokhimiia

SN - 0006-2979

IS - 3

ER -